Vesilute is a peptide bioregulator targeting bladder epithelial tissue (urothelium) — one of the more specialized organ-specific peptides in the Khavinson bioregulator series developed at the St. Petersburg Institute of Bioregulation and Gerontology. As a tissue-specific short peptide derived from bladder tissue, Vesilute activates gene expression in urothelial cells that has been progressively silenced by aging, chronic mechanical stress, recurrent infection, and inflammatory damage — the epigenetic root of the age-related bladder dysfunction that affects a substantial portion of aging populations.

The urothelium is a highly specialized transitional epithelium with unique structural properties: it must be impermeable to urine components (ions, urea, organic acids) while withstanding continuous mechanical stretch and relaxation as the bladder fills and empties. Urothelial cells express specialized proteins — uroplakins (UP Ia, Ib, II, III), tight junction components, and barrier lipids — that maintain this impermeability. With aging, expression of these barrier genes progressively declines, leading to urothelial permeability increases, penetration of urine components into the bladder wall, sensory nerve sensitization, and the urgency, frequency, and pain symptoms characteristic of bladder aging syndrome.

Vesilute's peptide sequence penetrates urothelial cell nuclei and reactivates transcription of these barrier and functional genes — uroplakin expression, tight junction proteins (claudins, occludins), anti-inflammatory genes that reduce sensory sensitization, and growth factors supporting urothelial self-renewal. The restoration of urothelial barrier integrity directly addresses the mechanism underlying overactive bladder symptoms, increased infection susceptibility, and the painful bladder conditions associated with urothelial compromise.

Khavinson group research on Vesilute has examined its effects in aging animal bladder tissue and in human populations with age-related lower urinary tract symptoms (LUTS). Animal studies demonstrate improved urothelial histology following Vesilute treatment — better preserved barrier architecture, higher uroplakin expression, and reduced inflammatory infiltration in bladder wall tissue. Human clinical outcomes include improvements in urinary frequency, reduced nocturia, improved bladder capacity, and reduced urinary urgency episodes — outcomes that directly improve quality of life for the substantial aging population affected by LUTS.

The mechanism is meaningfully different from anticholinergic drugs and beta-3 agonists used for overactive bladder: those compounds reduce detrusor muscle contractility or block muscarinic receptors to suppress urgency symptoms. Vesilute addresses the upstream urothelial barrier dysfunction that sensitizes sensory nerves and drives the urgency sensation — a causal intervention rather than symptomatic management. For post-menopausal women and aging men where urothelial atrophy is a significant contributor to LUTS, Vesilute's epigenetic restoration approach targets the actual tissue pathology.

Protocol: 2mg/day for 10 consecutive days, subcutaneous or intranasal, repeated 2–4 times per year.